Metabotropic glutamate receptor 5 (mGluR5) regulates the translation of amyloid precursor protein (APP) mRNA. Under resting conditions, mRNA is bound to and translationally repressed by the fragile X mental retardation protein (FMRP). Upon group 1 mGluR activation, FMRP dissociates from the mRNA and translation ensues. APP levels are elevated in the dendrites of primary neuronal cultures as well as in synaptoneurosomes (SN) prepared from embryonic and juvenile fmr-1 knockout (KO) mice, respectively. In order to study the effects of APP and its proteolytic product Aβ on Fragile X syndrome (FXS) phenotypes, we created a novel mouse model (FRAXAD) that over-expresses human APPSwe/Aβ in an fmr-1 KO background. Herein, we assess (1) human APPSwe and Aβ levels as a function of age in FRAXAD mice, and (2) seizure susceptibility to pentylenetetrazol (PTZ) after mGluR5 blockade. PTZ-induced seizure severity is decreased in FRAXAD mice pre-treated with the mGluR5 antagonist MPEP. These data suggest that Aβ contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients.
|Original language||English (US)|
|Number of pages||13|
|Journal||International Journal of Clinical and Experimental Pathology|
|State||Published - Sep 7 2010|
ASJC Scopus subject areas
- Pathology and Forensic Medicine